Pinpointing the causal links between targets and cancer
 

Our mission is to develop in silico data packages containing characterized and prioritized targets & biomarkers with critical evidence, for outlicensing to biotech and biopharma.

 

We have bespoke technology that identifies key pathway drivers and supports indication expansion, patient stratification, synthetic lethality and combination therapies

​

​

​

Our oncology pipeline

​

​

​

​

​

​

​

​

​

​

​

Watch our Head of Biology briefly introduce our latest results in ALaSCAdb 

​

​

Using ALaSCA, we were able to successfully analyse the contributions of different DNA repair pathways and programmed cell death pathways across several treatment regimes. The causal AI results are helping us narrow down the potential mechanism of action of our therapy on glioblastoma cell lines as well as identifying potential targets to test in the future for synergistic therapy.

Leading glioblastoma researcher

​